The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Isoprenoids as mediators of the biological effects of statins
Open accessAbstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol biosynthesis.Several large clinical trials have demonstrated the benefits of cholesterol lowering with these agents in the primary and secondary prevention of coronary heart disease.The overall clinical benefits observed with statin therapy, however, appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels.Recent experimental and clinical evidence indicates that some of the cholesterol-independent, or so-called pleiotropic, effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response in the vascular wall.Many of these cholesterolindependent effects reflect statins' ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules.In particular, the inhibition of small GTP-binding proteins Rho, Ras, and Rac, whose proper membrane localization and function are dependent upon isoprenylation, may play an important role in mediating the biological effects of statins. Pharmacological properties of statinsStatins bind to HMG-CoA reductase at nanomolar concentrations, leading to competitive displacement of the natural substrate, HMG-CoA, which binds at micromolar concentrations (1).In addition, inhibition of cholesterol biosynthesis is accompanied by an increase in hepatic LDL receptor, which promotes uptake and clearance of cholesterol from the bloodstream.While all statins inhibit hepatic HMG-CoA reductase to varying degrees, important structural differences exist among the statins that distinguish their lipophilicity, half-life, and potency (2).For example, one of the more potent newer statins, rosuvastatin, is relatively hydrophilic and has a greater number of bonding interactions with the catalytic site of HMG-CoA reductase compared with mevastatin, fluvastatin, simvastatin, cerivastatin, and atorvastatin (1, 3).The lipophilic statins would be expected to penetrate cell membranes more effectively than the more hydrophilic statins, causing more side effects but, at the same time, eliciting more pleiotropic effects.However, the observation that hydrophilic statins have pleiotropic effects similar to those of lipophilic statins calls into question whether there are really any cholesterol-independent effects of statins.Indeed, recent evidence suggests that some of the cholesterol-independent effects of these agents may be mediated by inhibition of hepatic HMG-CoA reductase, leading to subsequent reduction in circulating isoprenoid levels (4).This hypothesis may help explain why hydrophilic statins such as pravastatin and rosuvastatin are still able to exert cholesterol-independent benefits on the vascular wall without directly entering vascular wall cells.In this respect, the word "pleiotropic" probably does not reflect the hepatic versus nonhepatic effects of these agents. Clinical trials with statinsBecause serum cholesterol level is strongly associated with coronary heart disease (5), it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects in cardiovascular diseases.However, subgroup analysis of large clinical trials such as the 4S, WOSCOP, CARE, and HPS suggests that the clinical benefits of statins are not associated with base-line cholesterol levels or the degree of cholesterol reduction (6-9).Furthermore, in angiographic trials, clinical improvements with statins far exceed changes in the size of atherosclerotic lesions (10).It is quite likely that cholesterol lowering in these longterm trials stabilized atherosclerotic plaques and made them less prone to rupture.However, in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, statins reduced recurrent ischemic events within 16 weeks following acute coronary ischemia (11).Although the serum LDL-cholesterol was decreased by 40%, this time frame was probably far too rapid for appreciable changes in lesion size and plaque stability to occur as a consequence of cholesterol reduction.An intriguing but perplexing result of large clinical trials with statins is the reduction in ischemic stroke ( 12).Although myocardial infarction is closely associated with serum cholesterol levels, neither the Framingham Heart Study nor the Multiple Risk Factor Intervention Isoprenoids as mediators of the biological effects of statins
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the effects of statins are connected with the inhibition of the synthesis of important isoprenoids, e.g.farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ subunit of heterotrimeric G-proteins [12] , guanosine triphosphatebinding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) [12][13][14] .”
From Statins as antifungal agents (2011) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Rho GTPases and signaling networksPreprint
Aelst, L. V., & D’Souza‐Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Contrast-Induced Acute Kidney Injury
McCullough, P. A., Choi, J. P., Feghali, G. A., SCHUSSLER, J. M., Stoler, R., Vallabahn, R. C., & Mehta, A. N. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.099 · Cited by 1,070
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature reviews. Immunology · doi:10.1038/nri1839 · Cited by 696
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 652
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464
Duivenvoorden, R., Tang, J., Cormode, D. P., Mieszawska, A. J., Izquierdo‐Garcia, D., Ozcan, C., Otten, M. J., Zaidi, N., Lobatto, M. E., van Rijs, S. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4065 · Cited by 448
Liao, J. K., Seto, M., & Noma, K. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318070d1bd · Cited by 402
Self-citationKruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells
SenBanerjee, S., Mir, S. S., Lin, Z., Hamik, A., Atkins, G. B., Das, H., Banerjee, P., Kumar, A., & Jain, M. K. (2005) · Circulation · doi:10.1161/circulationaha.104.525774 · Cited by 348
Breast Cancer Growth Prevention by Statins
Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F. L., Kumar, A. S., Adduci, K., Marx, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4061 · Cited by 353
Cholesterol in Alzheimer's disease
Shobab, L. A., Hsiung, G. R., & Feldman, H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70248-9 · Cited by 351
Role of Cholesterol in the Development and Progression of Breast Cancer
Llaverı́as, G., Danilo, C., Mercier, I., Daumer, K. M., Capozza, F., Williams, T. M., Sotgia, F., Lisanti, M. P., & Frank, P. G. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.005 · Cited by 327
Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism
Bertolio, R., Napoletano, F., Mano, M., Maurer‐Stroh, S., Fantuz, M., Zannini, A., Bicciato, S., Sorrentino, G., & Sal, G. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09152-7 · Cited by 304
Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Kukar, T. L., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T. B., Khan, M. A., Kache, R., Beard, J. D., et al. (2005) · Nature Medicine · doi:10.1038/nm1235 · Cited by 290
Aktaş, O., Waiczies, S., Тихоновна, С. А., Dörr, J. R., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021425 · Cited by 280
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 274
Toxicity of statins on rat skeletal muscle mitochondria
Kaufmann, P., Török, M., Zahno, A., Waldhauser, K. M., Brecht, K., & Krähenbühl, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6235-z · Cited by 263
Statins and the vascular endothelial inflammatory response
Greenwood, J., & Mason, J. C. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.12.003 · Cited by 262
Statins Exert Endothelial Atheroprotective Effects via the KLF2 Transcription Factor
Parmar, K. M., Nambudiri, V. E., Dai, G., Larman, H. B., Gimbrone, M. A., & García‐Cardeña, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500144200 · Cited by 255
The vulnerable atherosclerotic plaque
Aikawa, M., & Libby, P. (2004) · Cardiovascular Pathology · doi:10.1016/s1054-8807(04)00004-3 · Cited by 242
Hewitt, R. E., Lissina, A., Green, A. E., Slay, E. S., Price, D. A., & Sewell, A. K. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02665.x · Cited by 239
Statins for the treatment of dementia
McGuinness, B., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 236
Mechanisms of plaque stabilization with statins
Libby, P., & Aikawa, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03267-8 · Cited by 228
Evidence for Statin Pleiotropy in Humans
Liu, P., Liu, Y.-W., Lin, L.-J., Chen, J.-H., & Liao, J. K. (2008) · Circulation · doi:10.1161/circulationaha.108.813311 · Cited by 224
Self-citationFluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
Garwood, E. R., Kumar, A. S., Baehner, F. L., Moore, D. H., Au, A., Hylton, N. M., Flowers, C. I., Garber, J. E., Lesnikoski, B., Hwang, E. S., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0507-x · Cited by 215
Dunn, S. E., Youssef, S., Goldstein, M. J., Prod’homme, T., Weber, M. S., Zamvil, S. S., & Steinman, L. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051129 · Cited by 213
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Kolavennu, V., Zeng, L., Peng, H., Wang, Y., & Danesh, F. R. (2007) · Diabetes · doi:10.2337/db07-1241 · Cited by 201
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
New Insights Into Molecular Mechanisms of Diabetic Kidney Disease
Badal, S. S., & Danesh, F. R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.047 · Cited by 183
Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.034 · Cited by 181
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Girolamo, F. G. D., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 188
Yeganeh, B., Wiecheć, E., Ande, S. R., Sharma, P. K., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M. M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?
Anagnostis, P. G., Karagiannis, A. I., Kakafika, A. I., Τζιόμαλος, Κ., Athyros, V. G., & Mikhailidis, D. P. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0648-5 · Cited by 171
Steinmetz, E. F., Buckley, C., Shames, M. L., Ennis, T. L., VanVickle-Chavez, S. J., Mao, D., Goeddel, L. A., Hawkins, C. J., & Thompson, R. W. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000150258.36236.e0 · Cited by 169
Kinlay, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.083 · Cited by 164
Pleiotropic effects of statins: A focus on cancer
Ahmadi, M., Amiri, S., Pecic, S., Machaj, F., Rosik, J., Łoś, M., Alizadeh, J., Mahdian, R., Rosa, S. C. D. S., Schaafsma, D., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165968 · Cited by 167
Sidaway, J. E., Davidson, R. G., McTaggart, F., Orton, T. C., Scott, R. C., Smith, G. J., & Brunskill, N. J. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000138236.82706.ee · Cited by 154
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle
Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154
Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment
Brennan, M., & Hazen, S. L. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200308000-00003 · Cited by 153
Ramasubbu, K., Estep, J. D., White, D. L., Deswal, A. M., & Mann, D. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.009 · Cited by 151
Role of Rac1–mineralocorticoid-receptor signalling in renal and cardiac disease
Nagase, M., & Fujita, T. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.282 · Cited by 155
Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?
Abeles, A. M., & Pillinger, M. H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21521 · Cited by 151
Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies
Hamerman, D. (2005) · QJM · doi:10.1093/qjmed/hci077 · Cited by 146
Statins as potential therapeutic agents in neuroinflammatory disorders
Stüve, O., Youssef, S., Steinman, L., & Zamvil, S. S. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000073942.19076.d1 · Cited by 141
Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
Bruinsmann, F. A., Pigana, S., Aguirre, T. A. S., Souto, G. D., Pereira, G. G., Bianchera, A., Fasiolo, L. T., Colombo, G., Marques, M. D. S., Pohlmann, A. R., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020086 · Cited by 140
Désiré, L., Bourdin, J., Loiseau, N., Peillon, H., Picard, V., Oliveira, C. D., Bachelot, F., Leblond, B., Taverne, T., Beausoleil, E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507913200 · Cited by 138
Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition
Argmann, C., Edwards, J. Y., Sawyez, C. G., O’Neil, C. H., Hegele, R. A., Pickering, J. G., & Huff, M. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502761200 · Cited by 130
Fong, C. W. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.037 · Cited by 136
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Borgquist, S., Giobbie‐Hurder, A., Ahern, T. P., Garber, J. E., Colleoni, M. A., Láng, I., Debled, M., Ejlertsen, B., von Moos, R., Smith, I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3116 · Cited by 128
Statin‐induced muscle damage and atrogin‐1 induction is the result of a geranylgeranylation defect
Cao, P., Hanai, J., Tanksale, P., Imamura, S., Sukhatme, V. P., & Lecker, S. H. (2009) · The FASEB Journal · doi:10.1096/fj.08-128843 · Cited by 117
Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., & Morishita, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102277 · Cited by 122
Simvastatin induces impairment in skeletal muscle while heart is protected
Sirvent, P., Bordenave, S., Vermaelen, M., Roels, B., Vassort, G., Mercier, J., Raynaud, E., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.108 · Cited by 116
New pharmacological treatments for improving renal outcomes in diabetes
Declèves, A., & Sharma, K. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.57 · Cited by 115
Simvastatin Inhibits Airway Hyperreactivity: Implications for the Mevalonate Pathway and Beyond
Zeki, A. A., Franzi, L. M., Last, J. A., & Kenyon, N. J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0018oc · Cited by 115
Cholesterol and statins in Alzheimer’s disease: current controversies.
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.013 · Cited by 93
Emerging views of statin pleiotropy and cholesterol lowering
Yu, D., & Liao, J. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab032 · Cited by 113
Self-citationBourdon, J. A., Halappanavar, S. S., Saber, A. T., Jacobsen, N. R., Williams, A., Wallin, H., Vogel, U. B., & Yauk, C. L. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs119 · Cited by 107
The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins
Murphy, C., Deplazes, E., Cranfield, C. G., & Garcia, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228745 · Cited by 119
Ahn, K. S., Sethi, G., & Aggarwal, B. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2507 · Cited by 107
Effects of lovastatin on breast cancer cells: a proteo-metabonomic study
Klawitter, J., Shokati, T., Moll, V., Christians, U., & Klawitter, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2485 · Cited by 103
Shimizu, K., Aikawa, M., Takayama, K., Libby, P., & Mitchell, R. N. (2003) · Circulation · doi:10.1161/01.cir.0000092949.67153.74 · Cited by 99
Statins: a role in breast cancer therapy?
Borgquist, S., Bjarnadottir, O., Kimbung, S., & Ahern, T. P. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12806 · Cited by 98
Ghavami, S., Mutawe, M. M., Sharma, P. K., Yeganeh, B., McNeill, K. D., Klonisch, T. C., Unruh, H. W., Kashani, H. H., Schaafsma, D., Łoś, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016523 · Cited by 94
Zimmet, P., & Thomas, C. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01170.x · Cited by 93
Statins downregulate myeloperoxidase gene expression in macrophages
Kumar, A. P., & Reynolds, W. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.204 · Cited by 94
Nagashima, T., Okazaki, H., Yudoh, K., Matsuno, H., & Minota, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21564 · Cited by 92
Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver
Moreno, M., Ramalho, L. N. Z., Sancho‐Bru, P., Ruiz‐Ortega, M., Ramalho, F. S., Abraldeṣ, J. G., Colmenero, J., Domínguez, M., Egido, J., Arroyo, V., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00462.2007 · Cited by 96
Statins for the treatment of dementia
McGuinness, B., O’Hare, J., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub2 · Cited by 93
Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E., Lacampagne, A., & Mercier, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.008 · Cited by 90
Statin myopathy: Incidence, risk factors, and pathophysiology
Sewright, K. A., Clarkson, P. M., & Thompson, P. D. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0050-3 · Cited by 90
Liang, K., Yin, S., Ting, C.-T., Lin, S., Hsueh, C., Chen, C.-Y., & Hsu, S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.034 · Cited by 89
Mullen, P. J., Lüscher, B., Scharnagl, H., Krähenbühl, S., & Brecht, K. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.007 · Cited by 88
Senokuchi, T., Matsumura, T., Sakai, M., Yano, M., Taguchi, T., Matsuo, T., Sonoda, K., Kukidome, D., Imoto, K., Nishikawa, T., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412531200 · Cited by 88
The role of statins in the differentiation and function of bone cells
Chamani, S., Liberale, L., Mobasheri, L., Montecucco, F., Al‐Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13534 · Cited by 90
Therapeutic targets in pulmonary arterial hypertension
Rhodes, C. J., Davidson, A., Gibbs, J. S. R., Wharton, J., & Wilkins, M. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.002 · Cited by 88
Ghavami, S., Mutawe, M. M., Hauff, K. D., Stelmack, G. L., Schaafsma, D., Sharma, P. K., McNeill, K. D., Hynes, T. S., Kung, S. K. P., Unruh, H. W., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.12.005 · Cited by 79
Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn's Disease
Grip, O., & Janciauskiene, S. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005263 · Cited by 80
Bocci, G., Fioravanti, A., Orlandi, P., Bernardini, N., Collecchi, P., Tacca, M. D., & Danesi, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602720 · Cited by 75
ROCKs as therapeutic targets in cardiovascular diseases
Rikitake, Y., & Liao, J. K. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.441 · Cited by 75
Self-citationThe beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
Saravi, S. S. S., Saravi, S. S. S., Arefidoust, A., & Dehpour, A. R. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0021-5 · Cited by 77
Paintlia, A. S., Paintlia, M. K., Singh, A. K., & Singh, I. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044230 · Cited by 74
Khattri, S., & Zandman‐Goddard, G. (2013) · Immunologic Research · doi:10.1007/s12026-013-8409-8 · Cited by 72
Wang, S. Y., Lee, S.-R., Guo, S., Kim, W. J., Montaner, J., Wang, X., & Lo, E. H. (2006) · Stroke · doi:10.1161/01.str.0000226923.48905.39 · Cited by 71
Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases
Chow, S. C. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0038-5 · Cited by 69
Singh, I., Paintlia, A. S., Khan, M., Stanislaus, R., Paintlia, M. K., Haq, E., Singh, A. K., & Contreras, M. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.059 · Cited by 72
Schaafsma, D., Dueck, G., Ghavami, S., Kroeker, A., Mutawe, M. M., Hauff, K. D., Xu, F. Y., McNeill, K. D., Unruh, H. W., Hatch, G. M., et al. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0052oc · Cited by 68
Zhang, X., Tao, Y., Troiani, L., & Markovic‐Plese, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100580 · Cited by 68
Statins in the treatment of central nervous system autoimmune disease
Weber, M. S., Youssef, S., Dunn, S. E., Prod’homme, T., Neuhaus, O., Stüve, O., Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.006 · Cited by 67
Poulsen, S. S., Saber, A. T., Mortensen, A., Szarek, J., Wu, D., Williams, A., Andersen, O., Jacobsen, N. R., Yauk, C. L., Wallin, H., et al. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.01.011 · Cited by 69
Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice
Mans, R. A., Chowdhury, N., Cao, D., McMahon, L. L., & Li, L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.12.062 · Cited by 67
The Nonlipid Effects of Statins on Endothelial Function
Beckman, J. A., & Creager, M. A. (2006) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.03.003 · Cited by 67
Effects of statins on the vasculature
Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03269-1 · Cited by 67
Therapy of Pulmonary Hypertension: The Evolution from Vasodilators to Antiproliferative Agents
Rubin, L. J. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2208008 · Cited by 67
Statins and breast cancer stage and mortality in the Women’s Health Initiative
Desai, P. M., Lehman, A., Chlebowski, R. T., Kwan, M. L., Arun, M., Manson, J. E., Lavasani, S. M., Wasswertheil-Smoller, S., Sarto, G. E., LeBoff, M. S., et al. (2015) · Cancer Causes & Control · doi:10.1007/s10552-015-0530-7 · Cited by 66
Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease
Fried, L. F. (2008) · Kidney International · doi:10.1038/ki.2008.231 · Cited by 65
Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
Schmitz, G., & Drobnik, W. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.088 · Cited by 64
Igarashi, J., Miyoshi, M., Hashimoto, T., Kubota, Y., & Kosaka, H. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707114 · Cited by 64
Inflammation and atherosclerosis
Shishehbor, M. H., & Bhatt, D. L. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0102-x · Cited by 63
Metadata
- Authors
- Liao, J. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Liao, James K.
- ORCID
- Liao, James K.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-01
- Volume
- 110
- Issue
- 3
- Pages
- 285-288
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4235797558
- Cited by
- 352
- References
- 35
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 16 · 2013: 13 · 2012: 16
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, terpenoids, pleiotropy, cholesterol-independent effects, HMG-CoA reductase inhibition, cholesterol biosynthesis, isoprenylation, small GTPases, Rho, Ras, Rac, endothelial function, atherosclerotic plaque stability, oxidative stress, inflammation, thrombogenicity, statin adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
